Electronic database to detect drug-drug interactions between antidepressants and oral anticancer drugs from a cancer center in Singapore: Implications to clinicians

Pharmacoepidemiology and Drug Safety

Volumn 20, Issue 9, 2011, Pages 939-947

  Chan, Alexandre ^a,b   Yap, Kevin Yi Lwern ^c   Koh, Dorothy ^a   Low, Xiu Hui ^a   Cheung, Yin Ting ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^c UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Antidepressants; Co prescription; Drug drug interactions; Oral anticancer drugs; Prevalence

Indexed keywords

ANASTROZOLE; ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT; BICALUTAMIDE; BUSULFAN; CAPECITABINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DIETHYLSTILBESTROL; ESTRAMUSTINE; ESTROGEN; ETOPOSIDE; EXEMESTANE; FLUDARABINE; FLUTAMIDE; GIMERACIL; HYDROXYUREA; LETROZOLE; LOMUSTINE; MEDROXYPROGESTERONE; MEGESTROL; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; NAVELBINE; NILUTAMIDE; NORETHISTERONE; OTERACIL; TEMOZOLOMIDE; UNINDEXED DRUG;

ADULT; ARTICLE; CANCER CENTER; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG INTERACTION; ELECTRONIC MEDICAL RECORD; FEMALE; HUMAN; INTERNET; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGAPORE;

EID: 84984590255     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2167     Document Type: Article

References (28)

1. Miller K, Massie MJ. Depression and anxiety. Cancer J 2006; 12: 388-397.
2. Miovic M, Block S. Psychiatric disorders in advanced cancer. Cancer 2007; 110: 1665-1676.
3. Ashbury FD, Madlensky L, Raich P, et al. Antidepressant prescribing in community cancer care. Support Care Cancer 2003; 11: 278-285.
4. Sandson NB, Armstrong SC, Cozza KL. An overview of psychotropic drug-drug interactions. Psychosomatics 2005; 46: 464-494.
5. Product Information. Novaldex (tamoxifen). AstraZeneca Pharmaceuticals LP: Wilmington, DE, 2007.
6. Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005; 97: 30-39.
7. DeMario MD, Ratain MJ. Oral chemotherapy: rationale and future directions. J Clin Oncol 1998; 16: 2557-2567.
8. Liu G, Franssen E, Fitch MI, et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15: 110-115.
9. O'Neill VJ, Twelves CJ. Oral cancer treatment: developments in chemotherapy and beyond. Br J Cancer 2002; 87: 933-937.
10. Weingart SN, Brown E, Bach PB, et al. NCCN Task Force Report: Oral chemotherapy. J Natl Compr Canc Netw 2008; 6(Suppl 3): S1-S14.
11. OncoRx: drug interactions with chemotherapy. [4th June 2010].
12. Yap KY, Ho YX, Chui WK, et al. Harnessing the internet cloud for managing drug interactions with chemotherapy regimens in patients with cancer suffering from depression. Acta Oncol 2010; 49: 1235-1245.
13. Tobi H, Faber A, van den Berg PB, et al. Studying co-medication patterns: the impact of definitions. Pharmacoepidemiol Drug Saf 2007; 16: 405-411.
14. Riechelmann RP, Tannock IF, Wang L, et al. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst 2007; 99: 592-600.
15. Product Information. Iressa (gefitinib). AstraZeneca Pharmaceuticals LP: Wilmington, DE, 2006.
16. Product Information. Tykerb (lapatinib). GlaxoSmithKline: Research Triangle Park, NC, 2009.
17. Product Information. Tarceva (erlotinib). Schwarz Pharma Manufacturing: Seymour, IN, 2008.
18. Product Information. Gleevec (imatinib). Novartis Pharmaceuticals Corporation: East Hanover, NJ, 2009.
19. Product Information. Prozac (fluoxetine). Eli Lilly and Company: Indianapolis, IN, 2008.
20. Product Information. Amitriptyline hydrochloride. Sandoz Inc: Princeton, NJ, 2007.
21. Kelly CM, Juurlink DN, Gomes T, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 2010; 340: c693.
22. Kivisto KT, Villikka K, Nyman L, et al. Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin. Clin Pharmacol Ther 1998; 64: 648-654.
23. Ferraldeschi R, Howell SJ, Thompson AM, et al. Avoidance of CYP2D6 inhibitors in patients receiving tamoxifen. J Clin Oncol 2010; 28: e584-e585; author reply e586.
24. Raschke RA, Gollihare B, Wunderlich TA, et al. A computer alert system to prevent injury from adverse drug events: development and evaluation in a community teaching hospital. JAMA 1998; 280: 1317-1320.
25. Seidling HM, Storch CH, Bertsche T, et al. Successful strategy to improve the specificity of electronic statin-drug interaction alerts. Eur J Clin Pharmacol 2009; 65: 1149-1157.
26. Pirmohamed M. Drug-drug interactions and adverse drug reactions: separating the wheat from the chaff. Wien Klin Wochenschr 2010; 122: 62-64.
27. Chan A, Tan SH, Wong CM, et al. Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: a Delphi survey of oncology pharmacists. Clin Ther 2009; 31(Pt 2): 2379-2386.
28. Isaac T, Weissman JS, Davis RB, et al. Overrides of medication alerts in ambulatory care. Arch Intern Med 2009; 169: 305-311.